Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT06280924
Recruiting Not applicable

Prehab Prior to Stem Cell Transplantation in Multiple Myeloma

NCT06280924 · tracked via the Priya Life Science Canada tracker
Sponsor
University of Alberta
Phase
Not applicable
Started
2024-08-06
Last updated
2026-02-06

Condition(s) studied

Multiple MyelomaExercisePrehabilitation

Investigational drug(s) / intervention(s)

Supported ExerciseStandard Care

Supported Exercise: Participants will take part in a prehabilitation exercise program prior to undergoing a stem cell transplant.

Standard Care: Participants will receive standard care

Study summary

The primary purpose of this study is to see if individuals with Multiple Myeloma are able and interested in taking part in a tailored exercise program while undergoing their chemotherapy prior to a stem cell transplant. We also hope to learn if this type of program, along with a flexible delivery format (in-person and virtual), helps in maintaining or improving physical fitness, muscle mass and strength, and quality of life during chemotherapy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Have a diagnosis of Multiple Myeloma 2. Be transplant eligible 3. Be undergoing chemotherapy prior to, or following an autologous stem cell transplant as part of their cancer treatment; or transplant ineligible. 4. Be an Alberta resident 5. Be ≥18 years of age 6. Be able to read and understand English. Exclusion Criteria: 1. Their disease status/comorbidities preclude exercise testing or participation 2. They are unable to commit to the 10-week exercise program and/or testing sessions at the Cancer Rehabilitation Clinic at the University of Alberta 3. They do not have regular access to the internet and/or an electronic device in the home.

Primary outcome measure(s)

  • Study completion rate — 10-weeks
    The percentage of participants who complete the study, including the intervention and follow-up assessment

Trial sites (1)

FacilityCityRegionStatus
University of Alberta/ Cross Cancer Institute Edmonton Alberta Recruiting

More University of Alberta trials in Canada

Multidisciplinary Team IntervenTion in CArdio-ONcology (TITAN Study) Active, not recruiting
Transcutaneous Spinal Cord Stimulation for Upper Extremity Function Recruiting
Protein Needs Study Recruiting
Multidisciplinary Support To Access Living Donor Kidney Transplant-Pilot Active, not recruiting
MinMed: Do Older Adults do Better With Less Medication Enrolling by invitation

Other trials for the same condition

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma Active, not recruiting
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Active, not recruiting
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma Recruiting
PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM) Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06280924 on ClinicalTrials.gov ↗ ← All trials in Canada